Deal Highlight – In October 2014, Aduro entered into its second agreement with Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, granting an exclusive, worldwide license to ADU-214 and other product candidates engineered for the treatment of lung cancer and certain other cancers based on Aduro’s novel LADD immunotherapy platform. Under the agreement facilitated by Johnson & Johnson Innovation center, Aduro received a $30 million up-front payment and a milestone payment associated with submission of the IND, and is eligible to receive future development, regulatory and commercialisation milestone payments up to a potential total of $786 million. In addition, Aduro is eligible to receive royalties at a rate ranging from high single-digits to low teens on worldwide net sales upon successful launch and commercialisation.
In Nov 2015 –
Aduro Biotech Inc. received a milestone payment from Janssen Biotech Inc. for the acceptance of Aduro’s Investigational New Drug (IND) application by the US Food and Drug Administration for ADU-214, a LADD immunotherapy product candidate for the treatment of lung cancer.